The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Are The Market Size Estimates For The Hemato Oncology Testing Market In 2026 And 2030?
The hemato oncology testing market has witnessed significant expansion in recent years. This market is set to increase from $3.93 billion in 2025 to $4.5 billion in 2026, reflecting a compound annual growth rate (CAGR) of 14.4%. The historical expansion of this market can be attributed to the escalating incidence of blood cancers, the broadening of hospital diagnostic laboratories, enhanced awareness of early cancer detection, an uptick in clinical research activities, and the availability of sophisticated testing reagents.
The hemato oncology testing market size is projected to experience swift expansion over the coming years. This market is anticipated to reach $7.76 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 14.6%. Factors contributing to this growth during the forecast timeframe include the growing acceptance of precision oncology diagnostics, increasing capital outlays in genomic testing infrastructure, the broadening of AI-powered diagnostic platforms, an escalating need for companion diagnostics, and ongoing advancements in assay technologies. Key trends expected within this period encompass the wider embrace of molecular diagnostic testing, the escalating application of next-generation sequencing in oncology, a heightened requirement for personalized cancer diagnostics, the proliferation of automated laboratory testing platforms, and improved incorporation of data analytics in hemato-oncology.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10075&type=smp
Which Drivers Are Supporting The Hemato Oncology Testing Market Growth?
The projected expansion of the hemato oncology testing market is fueled by the rising occurrence of hematologic cancer. Hematologic cancer encompasses various malignancies that develop in the blood, bone marrow, and lymphatic system, such as leukemia, lymphoma, and myeloma. Early detection, facilitated by hemato oncology testing, plays a crucial role in mitigating the impact of these conditions. For example, data from Cancer Research UK, a UK-based charity, published in September 2025, indicates that the leukemia incidence rate in the UK is estimated at roughly 17.9 cases per 100,000 people per year between 2024 and 2026. This figure is forecast to drop by 3% to approximately 17.4 per 100,000 by the period of 2038 to 2040. Consequently, the growing prevalence of hematologic cancer is a key factor propelling the expansion of the hemato oncology testing market.
Which Segment Types Are Examined In The Hemato Oncology Testing Market Segment Study?
The hemato oncology testing market covered in this report is segmented –
1) By Product And Services: Assay Kits And Reagents, Services
2) By Cancer Type: Leukemia, Lymphoma, Multiple Myeloma
3) By Technology: Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), Next-Generation Sequencing (NGS)
4) By End User: Hospitals, Academic And Research Institutes
Subsegments:
1) By Assay Kits And Reagents: PCR Kits, Next-Generation Sequencing (NGS) Kits, Flow Cytometry Reagents, Antibodies
2) By Services: Testing Services, Data Analysis Services
Which Trends Are Expected To Impact The Hemato Oncology Testing Market?
Major companies operating in the hemato-oncology testing market are rolling out new innovations, such as next-generation sequencing (NGS), to enhance the accuracy and speed of genetic analysis, enable comprehensive profiling of hematologic malignancies, and facilitate personalized treatment strategies tailored to individual patient needs. Next-generation sequencing (NGS) is a high-throughput DNA sequencing technology that allows for the rapid and cost-effective analysis of entire genomes or targeted regions of DNA. For instance, in October 2024, NeoGenomics Inc., a US-based cancer diagnostics and genomic testing company, unveiled AML Express, a next-generation sequencing (NGS) tool designed for the swift detection of mutations associated with Acute Myeloid Leukemia (AML). This sophisticated diagnostic platform offers superior accuracy and quick turnaround, supporting oncologists in making prompt, targeted treatment decisions. AML Express aims to elevate patient outcomes by providing precise mutation insights customized to AML-specific genetic profiles.
Which Players Are Part Of The Competitive Landscape Of The Hemato Oncology Testing Market?
Major companies operating in the hemato oncology testing market are F. Hoffmann-La Roche Ltd., Abbott Laboratories, Thermo Fisher Scientific Inc., Illumina Inc., Invivoscribe Inc., Qiagen N.V., Bio-Rad Laboratories Inc., Archerdx Inc., ARUP Laboratories Inc., Asuragen Inc., Adaptive Biotechnologies Corp., Cepheid Inc., EntroGen Inc., CORE Diagnostics Inc., Genoptix Inc., GenPath Diagnostics, NeoGenomics Laboratories Inc., Siemens AG, Sysmex Corporation, Laboratory Corporation of America Holdings, Agilent Technologies, Danaher Corporation, Grifols SA, Diaorin SpA, HTG Molecular Diagnostics Inc., Admera Health
Get The Full Hemato Oncology Testing Market Report:
https://www.thebusinessresearchcompany.com/report/hemato-oncology-testing-global-market-report
Which Region Is The Top Contributor To The Hemato Oncology Testing Market By Share?
North America was the largest region in the hemato oncology testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global hemato oncology testing market report during the forecast period. The regions covered in the hemato oncology testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Hemato Oncology Testing Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/customise?id=10075&type=smp
Browse Through More Reports Similar to the Global Hemato Oncology Testing Market 2026, By The Business Research Company
Hematocrit Test Devices Market Report 2026
https://www.thebusinessresearchcompany.com/report/hematocrit-test-devices-global-market-report
Dermatological Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/dermatological-drugs-global-market-report
Hematology Drug Market Report 2026
https://www.thebusinessresearchcompany.com/report/hematology-drug-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model